Skip to main content

Advertisement

SpringerLink
Log in

Combined intravitreal bevacizumab and photodynamic therapy for neovascular age-related macular degeneration

  • Clinical Investigation
  • Published:
Graefe's Archive for Clinical and Experimental Ophthalmology Aims and scope Submit manuscript

Abstract

Background

Our aim was to evaluate the short-term safety and efficacy of combined photodynamic therapy (PDT) with verteporfin and intravitreal bevacizumab in neovascular age-related macular degeneration (AMD).

Methods

A prospective non-randomized interventional case series of 30 eyes of 30 patients with choroidal neovascularization (CNV) caused by AMD was studied. All patients were treated with PDT followed by an intravitreal injection of bevacizumab (1.5 mg) on the same day. Ophthalmic evaluations included determination of best-corrected visual acuity by using ETDRS charts. CNV lesion characteristics were determined by fluorescein angiography, and retinal morphology by optical coherence tomography. Review examinations were performed 1, 4, and 12 weeks following treatment.

Results

The median ETDRS letter scores increased by 3 letters after 4 weeks and 4.3 letters after 12 weeks. Median central retinal thickness decreased from the baseline by 145 μm (week 1), 205 μm (week 4), and 171 μm (week 12), respectively (P < 0.0001, for all comparisons). One patient experienced a transient moderate vision loss after 4 weeks post treatment. Leakage on fluorescein angiography was resolved in all patients at week 12. No significant ocular or systemic side-effects were observed.

Conclusions

Short-term results suggest that a single PDT in combination with intravitreal bevacizumab is safe and associated with stabilization of visual acuity and decrease of intraretinal and subretinal fluid accumulation in the macula. Further evaluation of this treatment strategy for neovascular AMD appears warranted.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
Fig. 9

Similar content being viewed by others

References

  1. Aiello LP, Brucker AJ, Chang S, Cunningham ET Jr, D’Amico DJ, Flynn HW Jr, Grillone LR, Hutcherson S, Liebmann JM, O’Brien TP, Scott IU, Spaide RF, Ta C, Trese MT (2004) Evolving guidelines for intravitreous injections. Retina 24:S3–S19

    Article  PubMed  Google Scholar 

  2. Augustin AJ, Schmidt-Erfurth U (2006) Verteporfin therapy combined with intravitreal triamcinolone in all types of choroidal neovascularization due to age-related macular degeneration. Ophthalmology 113:14–22

    Article  PubMed  Google Scholar 

  3. Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ (2006) Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 113:363–372

    Article  PubMed  Google Scholar 

  4. Blinder KJ, Bradley S, Bressler NM, Bressler SB, Donati G, Hao Y, Ma C, Menchini U, Miller J, Potter MJ, Pournaras C, Reaves A, Rosenfeld PJ, Strong HA, Stur M, Su XY, Virgili G (2003) Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP report no. 1. Am J Ophthalmol 136:407–418

    Article  PubMed  CAS  Google Scholar 

  5. Bressler NM (2001) Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2. Arch Ophthalmol 119:198–207

    PubMed  CAS  Google Scholar 

  6. Framme C, Flucke B, Birngruber R (2006) Comparison of reduced and standard light application in photodynamic therapy of the eye in two rabbit models. Graefes Arch Clin Exp Ophthalmol 244:773–781

    Article  PubMed  CAS  Google Scholar 

  7. TAP Study Group (1999) Photodynamic therapy of subfoveal choroidal neovascularization in agerelated macular degeneration with verteporfin: one-year results of 2 randomized clinical trials–TAP report. Treatment of Age-related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Arch Ophthalmol 117:1329–1345

    Google Scholar 

  8. Hoffmann S, Masood R, Zhang Y, He S, Ryan SJ, Gill P, Hinton DR (2000) Selective killing of RPE with a vascular endothelial growth factor chimeric toxin. Invest Ophthalmol Vis Sci 41:2389–2393

    PubMed  CAS  Google Scholar 

  9. Holz FG, Pauleikhoff D, Klein R, Bird AC (2004) Pathogenesis of lesions in late age-related macular disease. Am J Ophthalmol 137:504–510

    Article  PubMed  Google Scholar 

  10. Husain D, Kramer M, Kenny AG, Michaud N, Flotte TJ, Gragoudas ES, Miller JW (1999) Effects of photodynamic therapy using verteporfin on experimental choroidal neovascularization and normal retina and choroid up to 7 weeks after treatment. Invest Ophthalmol Vis Sci 40:2322–2331

    PubMed  CAS  Google Scholar 

  11. Husain D, Kim I, Gauthier D, Lane AM, Tsilimbaris MK, Ezra E, Connolly EJ, Michaud N, Gragoudas ES, O’Neill CA, Beyer JC, Miller JW (2005) Safety and efficacy of intravitreal injection of ranibizumab in combination with verteporfin PDT on experimental choroidal neovascularization in the monkey. Arch Ophthalmol 123:509–516

    Article  PubMed  Google Scholar 

  12. Jaissle GB, Szurman P, Bartz-Schmidt KU (2005) Recommendation for the implementation of intravitreal injections—statement of the German Retina Society, the German Society of Ophthalmology (DOG) and the German Professional Association of Ophthalmologists (BVA). Klin Monatsbl Augenheilkd 222:390–395

    Article  PubMed  CAS  Google Scholar 

  13. Jonas JB (2005) Intravitreal triamcinolone acetonide for treatment of intraocular oedematous and neovascular diseases. Acta Ophthalmol Scand 83:645–663

    Article  PubMed  Google Scholar 

  14. Kaiser PK, Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group (2006) Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: 5-year results of two randomized clinical trials with an open-label extension: TAP report no. 8. Graefes Arch Clin Exp Ophthalmol 244:1132–1142

    Article  PubMed  CAS  Google Scholar 

  15. Kamba T, Tam BY, Hashizume H, Haskell A, Sennino B, Mancuso MR, Norberg SM, O’Brien SM, Davis RB, Gowen LC, Anderson KD, Thurston G, Joho S, Springer ML, Kuo CJ, McDonald DM (2006) VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. Am J Physiol Heart Circ Physiol 290:H560–H576

    Article  PubMed  CAS  Google Scholar 

  16. Kent D, Sheridan C (2003) Choroidal neovascularization: a wound healing perspective. Mol Vis 9:747–755

    PubMed  CAS  Google Scholar 

  17. Kim IK, Husain D, Michaud N, Connolly E, Lane AM, Durrani K, Hafezi-Moghadam A, Gragoudas ES, O’Neill CA, Beyer JC, Miller JW (2006) Effect of intravitreal injection of ranibizumab in combination with verteporfin PDT on normal primate retina and choroid. Invest Ophthalmol Vis Sci 47:357–363

    Article  PubMed  Google Scholar 

  18. Kramer M, Miller JW, Michaud N, Moulton RS, Hasan T, Flotte TJ, Gragoudas ES (1996) Liposomal benzoporphyrin derivative verteporfin photodynamic therapy. Selective treatment of choroidal neovascularization in monkeys. Ophthalmology 103:427–438

    PubMed  CAS  Google Scholar 

  19. Michels S, Hansmann F, Geitzenauer W, Schmidt-Erfurth U (2006) Influence of treatment parameters on selectivity of verteporfin therapy. Invest Ophthalmol Vis Sci 47:371–376

    Article  PubMed  Google Scholar 

  20. Michels S, Rosenfeld PJ, Puliafito CA, Marcus EN, Venkatraman AS (2005) Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twelve-week results of an uncontrolled open-label clinical study. Ophthalmology 112:1035–1047

    Article  PubMed  Google Scholar 

  21. Michels S, Schmidt-Erfurth U (2003) Sequence of early vascular events after photodynamic therapy. Invest Ophthalmol Vis Sci 44:2147–2154

    Article  PubMed  Google Scholar 

  22. Moshfeghi DM, Kaiser PK, Grossniklaus HE, Sternberg P Jr, Sears JE, Johnson MW, Ratliff N, Branco A, Blumenkranz MS, Lewis H (2003) Clinicopathologic study after submacular removal of choroidal neovascular membranes treated with verteporfin ocular photodynamic therapy. Am J Ophthalmol 135:343–350

    Article  PubMed  CAS  Google Scholar 

  23. Nozaki M, Sakurai E, Raisler BJ, Baffi JZ, Witta J, Ogura Y, Brekken RA, Sage EH, Ambati BK, Ambati J (2006) Loss of SPARC-mediated VEGFR-1 suppression after injury reveals a novel antiangiogenic activity of VEGF-A. J Clin Invest 116:422–429

    Article  PubMed  CAS  Google Scholar 

  24. Postelmans L, Pasteels B, Coquelet P, El Ouardighi H, Verougstraete C, Schmidt-Erfurth U (2004) Severe pigment epithelial alterations in the treatment area following photodynamic therapy for classic choroidal neovascularization in young females. Am J Ophthalmol 138:803–808

    Article  PubMed  Google Scholar 

  25. Rechtman E, Danis RP, Pratt LM, Harris A (2004) Intravitreal triamcinolone with photodynamic therapy for subfoveal choroidal neovascularisation in age related macular degeneration. Br J Ophthalmol 88:344–347

    Article  PubMed  CAS  Google Scholar 

  26. Rosenfeld PJ, Moshfeghi AA, Puliafito CA (2005) Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 36:331–335

    PubMed  Google Scholar 

  27. Schmidt-Erfurth U, Miller JW, Sickenberg M, Laqua H, Barbazetto I, Gragoudas ES, Zografos L, Piguet B, Pournaras CJ, Donati G, Lane AM, Birngruber R, Berg H van den, Strong HA, Manjuris U, Gray T, Fsadni M, Bressler NM (1999) Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of retreatments in a phase 1 and 2 study. Arch Ophthalmol 117:1177–1187

    PubMed  CAS  Google Scholar 

  28. Schmidt-Erfurth U, Laqua H, Schlotzer-Schrehard U, Viestenz A, Naumann GO (2002) Histopathological changes following photodynamic therapy in human eyes. Arch Ophthalmol 120:835–844

    PubMed  Google Scholar 

  29. Schmidt-Erfurth U, Schlotzer-Schrehard U, Cursiefen C, Michels S, Beckendorf A, Naumann GO (2003) Influence of photodynamic therapy on expression of vascular endothelial growth factor (VEGF), VEGF receptor 3, and pigment epithelium-derived factor. Invest Ophthalmol Vis Sci 44:4473–4480

    Article  Google Scholar 

  30. Spaide RF, Sorenson J, Maranan L (2003) Combined photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide for choroidal neovascularization. Ophthalmology 110:1517–1525

    Article  PubMed  Google Scholar 

  31. Spaide RF, Sorenson J, Maranan L (2005) Photodynamic therapy with verteporfin combined with intravitreal injection of triamcinolone acetonide for choroidal neovascularization. Ophthalmology 112:301–304

    Article  PubMed  Google Scholar 

  32. Spaide RF, Laud K, Fine HF, Klancnik JM Jr, Meyerle CB, Yannuzzi LA, Sorenson J, Slakter J, Fisher YL, Cooney MJ (2006) Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 26:383–390

    Article  PubMed  Google Scholar 

  33. Wachtlin J, Behme T, Heimann H, Kellner U, Foerster MH (2003) Concentric retinal pigment epithelium atrophy after a single photodynamic therapy. Graefes Arch Clin Exp Ophthalmol 241:518–521

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Ophthalmology, University of Bonn, Ernst-Abbe-Strasse 2, 53127, Bonn, Germany

    Markus S. Ladewig, Stefanie E. Karl, Victoria Hamelmann, Hans-Martin Helb, Hendrik P. N. Scholl, Frank G. Holz & Nicole Eter

Authors
  1. Markus S. Ladewig
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stefanie E. Karl
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Victoria Hamelmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hans-Martin Helb
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hendrik P. N. Scholl
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Frank G. Holz
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Nicole Eter
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Frank G. Holz.

Additional information

None of the authors has a financial interest in the subject matter of the article.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ladewig, M.S., Karl, S.E., Hamelmann, V. et al. Combined intravitreal bevacizumab and photodynamic therapy for neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 246, 17–25 (2008). https://doi.org/10.1007/s00417-007-0654-x

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00417-007-0654-x

Keywords

Search

Navigation